Abstract: A system for tracking relative displacement between a first element and a second element in a structure, the system includes: a permanent magnet fixed relative to the first element; a magnetic sensor fixed relative to the second element, the magnetic sensor configured to measure a magnetic field strength; and a processor configured to determine the relative displacement between the first element and the second element, based on the magnetic field strength measured by the magnetic sensor. This invention has particular applications in e.g. orthopaedic prostheses. A related method includes the steps of measuring, using the magnetic sensor, a magnetic field strength; and determining the relative displacement between the relative displacement between the first element and the second element, based on the magnetic field strength measured by the magnetic sensor.

Abstract: The present invention relates to pharmaceutical composition comprising dimethyl fumarate; an enzyme modulator or a permeation enhancer or both; and one or more pharmaceutically acceptable excipients. It further relates to a pulsatile release pharmaceutical composition comprising dimethyl fumarate and one or more pharmaceutically acceptable excipients. The compositions of the present invention are administered at a lower dose as compared to the recommended daily dose of Tecfidera®. Further, the compositions of the present invention are resistant to dose dumping in the presence of alcohol.

Abstract: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.

Abstract: The present invention relates to topical aqueous spray compositions of halobetasol. The topical aqueous spray compositions may be in the form of solutions or emulsions. It also relates to processes for the preparation of the topical aqueous spray compositions. It further relates to a method of treating topical skin conditions by administering said topical aqueous spray compositions.

Abstract: The present invention provides an oral pharmaceutical composition of isotretinoin having enhanced bioavailability, wherein said composition is in the form of a solid dispersion comprising isotretinoin and a pharmaceutically acceptable matrix. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.

Abstract: The present invention relates to a topical solution comprising a retinoid or its pharmaceutically acceptable salts thereof and process of preparing it.

Abstract: The present invention provides, among other things, forms of a compound of formula 1. In some embodiments, the present invention provides salt forms and/or crystal forms. In some embodiments, the present invention provides solid forms. The present invention also provides methods of making and using provided forms.

Abstract: The present invention relates to improved methods of resolution and recrystallization for synthesizing compounds useful as 5HT2C agonists or partial agonists, including intermediates thereto.

Abstract: Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4?-fluoro-2?-oxo-1?,2?-dihydrospiro[cyclopropane-1,3?-indol]-5?-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, hormone-dependent carcinomas; treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; or treating symptoms of premenstrual syndrome using one or more of these polymorphs, solvates, or hydrate.

Abstract: The present invention relates to one or more crystalline forms and polymorphs of compounds of formula I: in the form of pharmaceutically acceptable salts. The present invention is directed to crystalline polymorphs and forms of specific anilino-pyrimidine benzenesulfonamide compounds of formula I as pharmaceutically acceptable salts.

Abstract: The present invention relates to methods for preparing one or more crystalline forms and polymorphs of a compound of formula I: and structurally related compounds. The present invention is also directed to methods for converting one polymorph to other different polymorphs of formula I and structurally related compounds.

Abstract: The present invention relates to methods for preparing one or more crystalline polymorphs of a compound of formula I: and structurally related compounds. The present invention is also directed to methods for converting one polymorph to other different polymorphs of formula I and structurally related compounds.

Abstract: The present invention relates to methods for preparing and manufacturing a crystalline form or polymorph of a compound of formula I: in the form of pharmaceutically acceptable salts and polymorphs thereof. The present invention is directed to methods for preparing and manufacturing crystalline polymorphs or forms of specific anilino-pyrimidine benzenesulfonamide compounds. Methods for converting one crystalline form or polymorph of compounds of formula I as their pharmaceutically acceptable salt polymorph to other different crystalline polymorphs of compounds of formula I as their corresponding pharmaceutically acceptable salt are also disclosed.

Abstract: A polymorph Form III of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form III are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form III of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. Also provided are methods for preparing polymorph Form I of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile from polymorph Form III of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile.

Abstract: A polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form II are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. Further provided are methods for preparing polymorph Form I of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile from polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile.

Abstract: The present invention provides a salt form, and compositions thereof, useful as a modulator of one or more GPCRs and which exhibits desirable characteristics for the same. The present invention also provides methods for preparing said salt form.

Abstract: The present invention provides purified crystalline CCI-779 and processes for preparing the same.

Abstract: Methods for purifying rapamycin are described. Methods for measuring particle quality, median particle size, and crystallinity of samples containing rapamycin or a derivative thereof are also provided.

Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.

Abstract: The present invention provides salt forms, and compositions thereof, useful as modulators of one or more GPCRs and which exhibit desirable characteristics for the same.